Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025
AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent productivity platform QINGDAO, China, April 30, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has officially published its 2025 annual report, posting full‑year revenue of 2.33 billion yuan (USD 340.77...
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
SHANGHAI, April 30, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be presented respectively as an oral presentation and a poster presentation, at the 2026 European Society for Medical Oncology...
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include: 2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months 2L+ colorectal cancer (CRC): ORR of 46.9%, mPFS of 9.5 months 2L+ pancreatic ductal adenocarcinoma...
CMEF 2026 wraps up in Shanghai: a global stage for medical breakthroughs and future trends
SHANGHAI, April 30, 2026 /PRNewswire/ -- The 93rd China International Medical Equipment Fair (CMEF), together with its concurrent industry events, has successfully concluded on April 12 at the National Exhibition and Convention Center (Shanghai) after four days of exhibitions and exchanges. Under the theme "Innovation Fusion, Boundless Evolution," the CMEF 2026 gathered over 300,000 participants from more than 150 countries and...
Taimei Technology Debuts at BioKorea 2026, Showcasing AI-Powered Clinical Research Solutions
SEOUL, South Korea, April 30, 2026 /PRNewswire/ -- Taimei Technology, a leading AI-driven drug clinical development platform, made its first public appearance in South Korea at BioKorea 2026, drawing significant attention with its advanced AI-powered clinical research technology solutions. Headquartered in China with established operations in Singapore and the United States, Taimei Technology is currently in the process of...
ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing in advanced immunology technologies. The partnership aims to comprehensively profile the function of approved anti-CD20 monoclonal antibodies (mAbs). The collaboration leverages ACROBiosystems' recombinant human full-length...
Ascletis to Present Data on Multiple Programs at the American Diabetes Association’s 2026 Scientific Sessions
HONG KONG, April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of...
ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates
TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, announces its collaboration with Carterra, a company focused on innovative technologies designed to accelerate the discovery of novel therapeutic antibodies. Through the synergy of ACROBiosystems' "FLAG" multi-pass transmembrane proteins and Carterra's LSA platform, large-scale comprehensive...
Frost & Sullivan Institute Announces Visionary Leadership Best Practices Recognition and This Year’s Honorees
SAN ANTONIO, April 30, 2026 /PRNewswire/ -- The Frost & Sullivan Institute (FSI) is pleased to unveil this year's recipients of the Visionary Leadership Best Practices Recognition. These individuals exemplify purpose-driven leadership, bold innovation, and measurable impact aligned with FSI's mission to inspire solutions that advance Education, Environment, Healthcare, Human Rights, Infrastructure, Security, and Economic Progress. These distinguished leaders...
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
TLX597-Tx is a PSMA-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification. Telix is developing two distinct prostate therapeutic programs, tailored to disease stage and patient condition: TLX591-Tx radio...
